Date of Award
1-1-2024
Document Type
Dissertation
Degree Name
Ph.D. in Pharmaceutical Sciences
First Advisor
Eman Ashour
Second Advisor
Mahmoud Elsohly
Third Advisor
Walter Chambliss
School
University of Mississippi
Relational Format
dissertation/thesis
Abstract
Cannabidiol (CBD) is a crystalline compound extracted from a high-CBD variety of the Cannabis sativa plant. It has various pharmacological effects, including antipsychotic, anti-inflammatory, anti-seizure, and anxiolytic properties. However, developing CBD formulations presents several challenges due to its high lipophilicity (log P of 6.3), poor water solubility (0.1 μg/mL), and significant first-pass metabolism, which results in low oral bioavailability, estimated at just 6%. Furthermore, research has demonstrated that CBD is susceptible to degradation from exposure to light, temperature, and oxidation during formulation. Currently, Epidiolex is the only commercially available preparation containing CBD that has been approved by the US-FDA for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome. Consequently, the aim of this study was to work on formulation development of CBD to increase its aqueous solubility and oral bioavailability by employing different techniques. This research focused on buccal drug delivery systems and nanostructured lipid carriers (NLCs) to address these issues. Hot melt extrusion (HME) has been employed in this research work, The results were promising, demonstrating significant improvements in both the solubility and oral bioavailability of CBD.
Recommended Citation
Taha, Iman, "Formulation Development of Cannabidiol Using Various Technologies as an Approach to Enhance its Solubility and Oral Bioavailability" (2024). Electronic Theses and Dissertations. 3030.
https://egrove.olemiss.edu/etd/3030
